Floatz logo

Ipilimumab

Recurrent Adult Immunoblastic Large Cell Lymphoma

Stanford Universitymonoclonal_antibodyPhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Adult Immunoblastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
University of Medicine and Dentistry of New Jersey
Phase 2BBB
VINCRISTINE SULFATE
University of Chicago
Phase 2BBB
DEXAMETHASONE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →